Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

Exploring the Role of Immunotherapy in Advanced Non-Small Cell Lung Cancer Without Targetable Mutations

Join Hossein Borghaei, DO, MS, Ramaswamy Govindan, MD, Charu Aggarwal, MD, MPH, and Jarushka Naidoo, MBBCh in a discussion on the role of immunotherapy in advanced non-small cell lung cancer without targetable mutations.

This activity is intended for hematologists/oncologists, pulmonologists, and pathologists.

The goal of this activity is that learners will have an increased awareness of immunotherapeutic regimens as first-line treatment for NSCLC and be better able to identify and manage immune-related adverse events using a multidisciplinary approach.
 


Learning Objectives:

  • Have increased knowledge regarding the
    • Rationale for using immunotherapy in early-stage NSCLC
    • Key clinical trial data evaluating immunotherapy in the treatment of early-stage NSCLC
  • Demonstrate greater confidence in their ability to
    • Understanding of the latest data on immunotherapy in the treatment of early-stage NSCLC

Approximate Time to Complete: 30 minutes

 

Credit Available: March 11, 2022 - March 11, 2023

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

Additional Resources for Clinicans from SITC:

 

 

Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the clinical trial data evaluating immunotherapy-containing regimens for frontline treatment of advanced non-small cell lung cancer (NSCLC) without actionable mutations.
  • Have increased knowledge regarding characteristics of dual immune checkpoint inhibitor therapy as frontline treatment for advanced NSCLC without actionable mutations.
  • Have greater competence related to tailoring frontline treatment for patients with advanced NSCLC without actionable mutations.
  • Demonstrate greater confidence in their ability to individualize frontline treatment for patients with advanced NSCLC without actionable mutations.
Accreditation Council for Continuing Medical Education and ABIM Maintenance of Certification
AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit: 0.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50
Accreditation Council for Pharmacy Education
CEU: 0.50